Guardant Health

Update in progress

GH (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Guardant Health is a precision oncology company that provides blood and tissue tests and data sets for the United States and international markets. Its offerings include Guardant360 CDx liquid biopsy for tumor mutation profiling; Guardant360 Liquid (740+ genes) and Guardant360 Tissue for multi-omic insights; Guardant Reveal ctDNA test; Shield colorectal cancer screening; GuardantINFINITY, GuardantOMNI, GuardantINFORM, and GuardantConnect software-enabled solutions; and a Smart Platform for integrated multiomic analysis. The company also provides development services, including companion diagnostics, regulatory support, clinical studies, licensing, and kit fulfillment. Based in Palo Alto, California, since 2011.

Company score

Sentiment: 0.98; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.04; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.94; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.31; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.65; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEODr. Helmy Eltoukhy Ph.D.
Founded2011
Employees2,490
Websiteguardanthealth.com

Identifiers

ISINUS40131M1099
FIGIBBG006D97VY9
LEI254900M8C3E5VC8BR186
CUSIP40131M109
CIK0001576280